B cells as therapeutic targets for rheumatic diseases

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

2003 • 2,387 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

2002 • 978 citations

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

2002 • 857 citations

A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine Lupus

1999 • 694 citations

A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

2003 • 592 citations

CD20: a regulator of cell-cycle progression of B lymphocytes

1994 • 583 citations

An open study of B lymphocyte depletion in systemic lupus erythematosus

2002 • 573 citations

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

2001 • 553 citations

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

2001 • 523 citations

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

2003 • 485 citations

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells

2003 • 469 citations

The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

2003 • 423 citations

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20

2003 • 370 citations

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

2001 • 362 citations

The role of B cells in lpr/lpr-induced autoimmunity.

1994 • 356 citations

Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance

2001 • 348 citations

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial

2002 • 332 citations

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

2003 • 285 citations

Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance

2001 • 277 citations

Rituximab treatment results in impaired secondary humoral immune responsiveness

2002 • 277 citations

Interleukin‐17 in rheumatoid arthritis: If T cells were to contribute to inflammation and destruction through synergy

2003 • 260 citations

Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma

2003 • 256 citations

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study

2003 • 246 citations

Rituximab in Idiopathic Membranous Nephropathy

2003 • 233 citations

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

2003 • 233 citations

The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.

1985 • 232 citations

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

2003 • 219 citations

The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

1985 • 178 citations

Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: Comparison of standing anteroposterior and Lyon Schuss views

2003 • 176 citations

Retention of B-cell-specific monoclonal antibodies by human lymphoma cells

1994 • 163 citations

The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus

2002 • 161 citations

VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype.

2002 • 149 citations

Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

2001 • 111 citations

Treatment of Intractable Rheumatoid Arthritis With Combined Cyclophosphamide, Azathioprine, and Hydroxychloroquine

1986 • 90 citations

CD154–CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus

2002 • 63 citations

Rituximab therapy for multisystem autoimmune diseases in pediatric patients

2003 • 51 citations

Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients.

2000 • 44 citations

Current Attitudes to the Therapy of Vasculitis

2003 • 37 citations

Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein

2002 • 34 citations

Therapeutic CD154 antibody for lupus: promise for the future?

2003 • 21 citations

Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases

2002 • 20 citations

6 Normal human B cell sub-populations and their malignant counterparts

1997 • 15 citations

Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study

1986 • 13 citations

Reply

2003 • 6 citations